FDA approves wider market for schizophrenia drug Saphris.
The drug was first approved in August 2009 for treating acute schizophrenia episodes in adults and acute mania or manic-depressive behavior in adults with bipolar disorder.
Merck says the FDA now has approved Saphris for ongoing treatment of schizophrenia and for treating acute mania or manic-depressive behavior in adult bipolar patients along with lithium, a mood-stabilizing drug often used to treat mania, or the antiseizure drug valproate.
This raises the perennial, but naive question "Who exactly is the Food and Drug Aministration working for?"
This news item has been brought to your attention courtesy of:
Sponsored LinksBipolar Depression Info
Learn About a Treatment Option & Get Questions to Ask Your Doctor.
Living With Bipolar?
Find Helpful Tools and Resources. Sign Up for a Support Program Now.
Buy a link here